Analyst Reco. Invivyd, Inc.

Equities

IVVD

US00534A1025

Real-time Estimate Cboe BZX Other stock markets 10:35:56 02/05/2024 pm IST			5-day change	1st Jan Change
2.36 ^USD	-2.48%		+13.04%	-40.61%

15/04	Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda	CI
12/04	Invivyd Names Jeremy Gowler as Interim CEO	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guggenheim Upgrades Invivyd to Buy From Hold, Price Target is $9	05/04	MT
Invivyd Receives Upgrade to Overweight From Equalweight From Morgan Stanley, Price Target Raised to $10 From $4 Amid Pemgarda FDA Authorization	26/03	MT
HC Wainwright Raises Price Target on Invivyd to $15 From $5, Keeps Buy Rating	18/01	MT
Morgan Stanley Upgrades Invivyd to Equal-Weight From Underweight, Raises Price Target to $4 From $1	19/12	MT
HC Wainwright Starts Invivyd at Buy With $5 Price Target	01/23/01	MT
Morgan Stanley Adjusts Price Target on Invivyd to $1 From $2, Maintains Underweight Rating	27/23/27	MT
Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating	24/23/24	MT
Stifel Adjusts Adagio Therapeutics' Price Target to $5 From $9, Reiterates Hold Rating	16/22/16	MT
Morgan Stanley Downgrades Adagio Therapeutics to Underweight Rating From Equalweight, Adjusts PT to $6 From $11	06/22/06	MT
Jefferies Downgrades Adagio Therapeutics to Hold From Buy; Price Target is $10	22/21/22	MT
Morgan Stanley Downgrades Adagio Therapeutics to Equalweight from Overweight, Adjusts Price Target to $11 from $49	15/21/15	MT
Guggenheim Downgrades Adagio Therapeutics to Neutral From Buy	15/21/15	MT
Stifel Downgrades Adagio Therapeutics to Hold From Buy, Adjusts Price Target to $9 From $50	15/21/15	MT
--Morgan Stanley Upgrades Adagio Therapeutics to Overweight From Equalweight; Price Target is $49; Shares Surge 70%	29/21/29	MT
Morgan Stanley Upgrades Adagio Therapeutics to Overweight From Equalweight; Price Target is $49	29/21/29	MT
Today on Wall Street: US tech giants return to top spot	31/21/31
ANALYST RECOMMENDATIONS : AT&T, BancorpSouth Bank, CMO Group, Magnite, Textron...	31/21/31
ADAGIO THERAPEUTICS : Morgan Stanley Starts Adagio Therapeutics at Equal-Weight With $33 Price Target	31/21/31	MT
ADAGIO THERAPEUTICS : Jefferies Starts Adagio Therapeutics at Buy With $60 Price Target	31/21/31	MT
ADAGIO THERAPEUTICS : Stifel Starts Adagio Therapeutics at Buy With $57 Price Target	31/21/31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Invivyd, Inc.

Equities

IVVD

US00534A1025

Analyst Reco.

Filters